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Heterogeneity in cancer guidelines: should we eradicate or
tolerate?
Abstract
BACKGROUND: Heterogeneity in aspects of development, structure and context of oncology
guidelines was not evaluated. We analysed and critically examined its implications. MATERIALS AND
METHODS: Nine cancer clinical practice guidelines were selected on the basis of popularity among
oncologists. The relevant Web sites and publications on three tumours were examined and
characteristics grouped in the data domains: producing organisation, methodology, guideline structure
and content, implementation and evaluation and scientific agreement. RESULTS: ASCO, ESMO, NICE,
SIGN, START, NHMRC, NCI, NCCN and CCO guidelines were examined. Development was initiated
by stakeholders or authorised bodies, run by task forces with varying degrees of multidisciplinarity, with
rare endorsement of external guidelines. Recommendation formulation was on the basis of evidence,
shaped via interactive processes of expert review and public consultation-based modifications.
Guidelines varied in comprehensiveness per tumour type, number, size, format, grading of evidence,
update and legal issues. Orientation for clinic use or as reference document, end-users and binding or
elective nature also varied. Standard dissemination strategies were used, though evaluation of adoption
and of impact on health outcomes was implemented with considerable heterogeneity. CONCLUSIONS:
Heterogeneity in development, structure, user and end points of guidelines is evident, though necessary
in order to meet divergent demands. Crucial for their effectiveness are adherence to methodological
standards, a clear definition of what the guideline intends to do for whom and a systematic evaluation of
their impact on health care.
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Background: Heterogeneity in aspects of development, structure and context of oncology guidelines was not
evaluated. We analysed and critically examined its implications.
Materials and methods: Nine cancer clinical practice guidelines were selected on the basis of popularity among
oncologists. The relevant Web sites and publications on three tumours were examined and characteristics grouped in
the data domains: producing organisation, methodology, guideline structure and content, implementation and
evaluation and scientific agreement.
Results: ASCO, ESMO, NICE, SIGN, START, NHMRC, NCI, NCCN and CCO guidelines were examined.
Development was initiated by stakeholders or authorised bodies, run by task forces with varying degrees of
multidisciplinarity, with rare endorsement of external guidelines. Recommendation formulation was on the basis of
evidence, shaped via interactive processes of expert review and public consultation-based modifications. Guidelines
varied in comprehensiveness per tumour type, number, size, format, grading of evidence, update and legal issues.
Orientation for clinic use or as reference document, end-users and binding or elective nature also varied. Standard
dissemination strategies were used, though evaluation of adoption and of impact on health outcomes was
implemented with considerable heterogeneity.
Conclusions: Heterogeneity in development, structure, user and end points of guidelines is evident, though
necessary in order to meet divergent demands. Crucial for their effectiveness are adherence to methodological
standards, a clear definition of what the guideline intends to do for whom and a systematic evaluation of their impact
on health care.
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introduction
Clinical practice guidelines (CPG) are defined as
‘‘systematically developed statements to assist practitioner and
patient decisions about appropriate health care for specific
clinical circumstances’’ [1]. The purposes of CPG are to
improve the quality of patient care and health care outcomes,
make clinical decisions more transparent, promote efficient use
of resources and prioritise research goals. Moreover, CPG may
aim to provide guidance for involved stakeholders (health
professionals, patients and carers, industry, health care
providers and policy makers) and support quality control [2, 3].
Oncology guidelines are nowadays produced by several
organisations and have been shown to improve both the care
process and patient outcomes in several studies [4, 5].
Increasing concern about the methodology, reporting and
quality of cancer guidelines provided the incentive for
international collaboration which led to the development of
tools and checklists [6]. These were intended to provide
standardised methods of development and reporting of
guidelines, of assessment of their quality and tools for
adaptation and implementation [7–11]. These features are
regarded as pivotal, since only high-quality, methodologically
sound, clear guideline statements are likely to be user-friendly
and adoptable by consumers [12]. In contrast, heterogeneity in
several aspects of guideline development is controversially seen.
It is regarded by some as an impediment to international
collaboration, to standardisation of methodology/quality
control and leading to duplication of efforts while other
investigators consider it a necessary tool for guideline flexibility,
adaptation and for meeting diverse needs [13–15]. In this study,
we sought to examine heterogeneity in several aspects of the
most commonly used oncology guidelines produced in English
language, critically analyse it and discuss its implications.
methods
Two on-line guideline databases (Guidelines International Network,
www.g-i-n.net, and National Guideline Clearinghouse, www.guideline.gov)
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as well as Web sites of professional health organisations and governmental
agencies were visited in order to identify oncology CPG produced in
English language. As our intention was not to produce a systematic review
of quality/structure of existing guidelines, our sample was neither global
(encompassing all guidelines) nor random. Instead, we chose to evaluate
the most commonly used oncology guidelines of the highest reputation and
popularity among practicing oncologists, as judged by a consensus survey
carried out between authors of this manuscript.
The quality of guidelines can be assessed by several suggested tools, of
which the AGREE (Appraisal of Guidelines Research and Evaluation)
instrument became popular and has been endorsed by the World Health
Organisation [7]. Appointing quality scores for the studied guidelines was
not our intention, as this has been done in the medical literature and can be
easily carried out by any interested person or party [16]. Instead, we sought
to provide descriptive characteristics of the nine examined guidelines in
order to highlight similarities and differences in their structure, format/
reporting, context, methodology, orientation/intent, scientific content and
evaluation and to critically analyse them. Accordingly, we recorded
guideline characteristics and classified them in the following data domains,
each containing a number of data modules: producing organisation (seven
modules), methodology (five modules), guideline structure and content (11
modules), implementation and evaluation (six modules). Moreover, we
sought to study the impact of heterogeneous guideline development
processes in the scientific content of formulated recommendations
(scientific agreement of formulated recommendations, 10 modules).
Relevant data were retrieved by visiting the Web sites of the producing
organisations. Information, statements and documents/publications that
contained data on the structure of the organisation and details on the
methodology followed for developing, reporting and implementing the
guidelines (GL) were studied. Moreover, three topic guidelines (advanced
lung cancer, advanced breast cancer, advanced colon cancer or guidelines of
similar topics) were scrutinised from each organisation so as to confirm or
refute guideline features described in methodology documents and to study
the agreement in the scientific content of formulated recommendations.
The principles and definitions below were applied in extracting, recording
and presenting data in each domain.
producing organisation characteristics
organisation and guideline web address. year of initiation. The earliest
publication year of any guideline was recorded.
body responsible for GL development. The expert panel, development group
or committee undertaking the task of developing a guideline.
proposal/decision for GL development. Data on individuals or groups
entitled to submit a proposal for GL development and on those taking the
final decision on the proposal.
check for duplication and potential endorsement of external GL. Explicit
statement whether the responsible body checked for presence of already
developed guidelines on the same topic from other organisations and
whether it analysed/considered them for potential endorsement.
funding. Source of financial support, exclusively or predominantly, for the
development of GL.
editorial independence from funding body. Presence of data or statements
affirming that views or interests of the funding body (government, industry,
charity or professional organisations) did not influence the guideline
recommendations.
methodology characteristics
composition of GL development group. Data on the professional skills of
individuals participating in the development group as well as on the
presence of methodological experts (statisticians, health economists,
information technology specialists, epidemiologists), patient/carer
representatives, representatives of policy makers (government) or industry.
review of the evidence. A literature review was defined as systematic only if
information such as search terms, time interval, selection criteria and
databases searched were set upfront before guideline development and were
provided. In the absence of the above, the literature review was termed
narrative.
process of GL development. An outline of the administrative/organisational
algorithm or process of guideline production.
consensus and authorship. Data on methods for reaching consensus and
processing disagreements between members of the responsible body for
guideline development. Upon explicit statement of use of consensus
techniques (Delphi, nominal group, consensus development conference or
others), the consensus was termed formal; otherwise, it was presumed to be
informal [17]. Authorship could involve one or several authors or
committee authorship (committee name furnished with members in an
appendix).
legal review. Check of the guideline draft by legal counsellors before
publication.
guideline structure and content characteristics
comprehensive for tumour type and site. CPG globally providing diagnosis,
staging and management recommendations for a solid tumour (i.e. CPG on
non-small-cell lung cancer (NSCLC) or lung cancer or advanced lung
cancer) in contrast to ‘narrow’ CPG focusing on specific topics within
a given solid tumour (i.e. second-line therapy for irresectable NSCLC,
chemoradiation for locally advanced NSCLC).
number of existing guidelines. As appearing online on 1 January 2008 and in
use.
advanced breast, colon, lung cancer. Presence or absence of a comprehensive
CPG on each of these tumour types with the year of issue. If
a comprehensive CPG is not present, number of guidelines with more
focused topics within the tumour type (in parentheses).
pages and references. Size of each full CPG version and number of references
cited (on the basis of the breast, colon and lung cancer CPG studied).
structure. Format of the guideline in thematic sections.
grading of evidence. Scales used to grade levels of evidence and strength of
recommendations. If none provided, the narrative approach summarily
describes characteristics and findings of clinical trials.
cost data. Information on cost, cost-effectiveness, cost utility or formal
health economic analyses.
literature search and update. Time interval for screening literature for
emergence of new relevant data and time interval for issue of an updated
guideline version.
conflict of interest stated. Explicit statement whether members of the
developing group have any financial, research or other interests potentially
conflicting with their property of independent guideline developers.
implementation and evaluation characteristics
use. Orientation for use of the CPG as a highly detailed reference source of
data/recommendations or as a short, flexible summary recommendation
tool for the clinic.
dissemination and implementation tools. Tools used to disseminate and
enhance adoption/implementation of the CPG among stakeholders.
original article Annals of Oncology
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binding for physicians. Statement whether physicians are legally bound to
adhere to guidelines.
targeted health professionals and range. Health workers for whom the CPG
were developed and geographic/political/cultural areas where relevant.
GL evaluation. Methods used and data produced on the implementation of
recommendations and on their impact on patient outcomes (survival,
quality of life, satisfaction), physician outcomes (adoption of GL,
satisfaction, quality care) and health system outcomes (cost-effectiveness,
optimal utilisation of resources).
scientific agreement of formulated recommendations
Similarities and differences in the scientific content of formulated
recommendations for the management of patients with NSCLC were
recorded by study of relevant guidelines produced by the nine
organisations. The modules that were examined were: Epidemiology,
Screening and presentation, Diagnosis, Staging, Surgery, Radiotherapy,
Chemotherapy, Other therapies (biologics), Palliative/supportive care,
Follow-up, Implementation and Research. The rate of agreement between
guidelines was scored in each module by the use of the following simple
scale:
0%–20%: Radically different
20%–40%: Numerous major differences
40%–60%: Some major differences
60%–80%: Only minor differences
80%–100%: Essentially identical
A mean score of agreement was calculated for each guideline. The SIGN
guidelines for NSCLC were randomly chosen to be used as the common
comparator for the remaining eight guidelines.
results
The CPG examined were those issued by the following:
ASCO (American Society of Clinical Oncology)
ESMO (European Society of Medical Oncology)
NICE (National Institute for Health and Clinical Excellence,
England and Wales)
SIGN (Scottish Intercollegiate Guidelines Network)
START (State of the Art Oncology in Europe, Italy)
NHMRC (National Health and Medical Research Council,
Australia)
NCI (National Cancer Institute, USA)
NCCN (National Comprehensive Cancer Network, USA)
CCO (Cancer Care Ontario, Canada)
producing organisation characteristics
Characteristics of the organisations responsible for production
of cancer CPG are shown in Table 1. Four professional
organisations of oncologists (ASCO, ESMO, START and
NCCN) and five government-funded multidisciplinary agencies
or institutes (NICE, SIGN, NHMRC, NCI and CCO) have been
developing CPG since the 1990s. A task force of 10–30
individuals with both expertise and motivation in applications
of evidence-based medicine actually constituted the workhorse
for development of CPG in virtually all organisations.
Differences were evident between organisations in the size of
the task forces (10 to >45 members) and the frequency of task
force meetings (ranging from one per year to monthly
sessions). These CPG development groups were appointed and
overseen by boards of experts and executives that lay higher in
the decision-making hierarchy of each organisation. The
proposals for new guideline development could stem from any
individual or society member in some organisations (ASCO,
ESMO, NICE, SIGN and NCCN), while only from registered
groups or relevant committees in others (START, NHMRC,
NCI and CCO). Detailed data on the body responsible for
CPG development and the decision-making hierarchical
structures of each organisation could be retrieved in all nine
cases. Only ASCO and NHMRC specifically stated that
a formal screen for existence of external, high-quality CPG on
the relevant topic was undertaken and that endorsement was
possible, after appropriate analysis and quality control. Still, in
both cases, it was the independent organisation that had
developed the external CPG that should apply to ASCO or
NHMRC for endorsement evaluation. Other societies did not
examine external CPG at all (ESMO, START, NCI and
NCCN) while others only used them as relevant evidence
upon which their own CPG were constructed (NICE, SIGN,
NHMRC and CCO). Financial support for the guideline
developmental process originated from either the budget of
professional organisations/societies (ASCO, ESMO, START
and NCCN) or grants issued by the government or
government-affiliated agencies (NICE, SIGN, NHMRC, NCI
and CCO). However, editorial independence from the funding
body, as well as this could be examined on the basis of legal
and administrative documents, the composition of
development groups, the reputation and expertise of involved
members and the statement of independence in produced
guidelines, was a pivotal prerequisite respected in all nine
organisations.
methodology characteristics
Characteristics of methods for guideline development are
shown in Table 2. The composition of the CPG development
group in NICE, SIGN, NHMRC and CCO was
multidisciplinary encompassing several professional
qualifications; they included medical, surgical and radiation
oncologists, other medical specialities, nurses, pharmacists,
psychologists, various methodological experts, health managers
or providers and patient/carer representatives. CPG working
groups from most other institutions included multidisciplinary
oncology specialists and some times, but not always,
methodological experts and patient representatives. No patient
representative involvement took place in ESMO, START and
NCI and was not consistent in ASCO and NCCN. No
methodological experts were present in development task forces
of ESMO, NCI and NCCN, while in START one statistical
editor operated across all panels. A consistent finding in all
development groups was nonparticipation of industry
representatives in order to safeguard the integrity of produced
recommendations. The review of relevant medical literature
was carried out systematically with a priori definition of search
strategy and strict selection criteria in the ASCO, NICE, SIGN,
NHMRC and CCO. A thorough literature search was carried
Annals of Oncology original article
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Table 1. Producing organisation characteristics
ASCO ESMO NICE SIGN START NHMRC NCI NCCN CCO
Organisation
and guideline
web address
American Society
of Clinical
Oncology http://
www.asco.org/
ASCO/Quality+
Care+%26+
Guidelines/Practice+
Guidelines/Clinical+
Practice+Guidelines
European Society
of Medical
Oncology http://
www.esmo.org/
resources/
clinicalguidelines/
National Institute
for Health and
Clinical Excellence
http://www.nice.
org.uk/guidance/
index.jsp?action=
byTopic&o=
7165&view=alI
Scottish Intercollegiate
Guidelines Network
http://www.sign.ac.uk/
guidelines/published/
index.html#Cancer
State of the
Art Oncology
in Europe http://
www.startoncology.
net/capitoli/default.
jsp?menu=
professional&
language=eng
National Health
and Medical
Research Council
http://www.
nhmrc.gov.au/
publications/
subjects/cancer.
htm
National Cancer
Institute http://
www.cancer.gov/
cancertopics/pdq/
cancerdatabase
National
Comprehensive
Cancer Network
http://www.nccn.
org/professionals/
physician_gls/f_
guidelines.asp?
button=I+Agree
Cancer Care
Ontario http://
www.cancercare.
on.ca/index_
practiceGuidelines
andEvidence
summaries.
htm
Year of initiation 1993 1999 1999 1996 1996 1995 Unknown 1996 1997
Body responsible
for GL
development
10- to 15-member
expert panel
appointed by the
ASCO Health
Services Committee
12- to 15-member
Guideline
Working Group
appointed by
the ESMO
Educational
Committee
13- to 30-member
Guideline
Development Group
appointed by the
NICE National
Collaborating Centre
for Cancer
15- to 25-member
Guideline Development
Group appointed by
the SIGN Executive
and chairman of
each group
START Steering
Committee and
START Scientific
Committee
appointed
by the Board of
Editors and the
Alliance Against
Cancer
NHMRC-
affiliated or
NHMRC-
registered
external bodies (30-50
members)
15- to 19-member
PDQ Editorial
Board appointed
by the NCI
28-member NCCN
Guideline Steering
Committee
appointed by the
NCCN Board
of Directors
Programme in
Evidence-Based
(PEBC) Disease
Site Group (23-33
members) and
Practice Guideline
Coordinating
Committee
(10 members)
appointed by CCO
Board of Directors
GL Development
Proposal/Decision
Any ASCO
member,
ASCO Health
Services Committee
Any ESMO
member,
Guideline
Working
Group
Any stakeholder,
Department of
Health
Any group or individual,
Guideline Programme
Advisory Group and
SIGN Council
START Steering
Committee and
Scientific Committee
Any registered
group. NHMRC
Council
NCI. PDQ
Editorial Boards
Any member of
NCCN institute,
NCCN Guideline
Steering Committee
Provincial Clinical
Standards,
Guidelines and
Quality Committee,
Board of Directors
Check for
duplication and
possible
endorsement
of external GL
Yes No No, other GL only
used as evidence
No, other GL only
used as evidence
No Yes No No No, other
GL only used
as evidence
Funding ASCO ESMO National Health
System, England
and Wales
National Health
System, Scotland
European School
of Oncology and
Alliance against
Cancer
NHMRC Federal
government
NCCN Consolidated
Revenue Fund
of the Government
of Ontario
Editorial
independence
from funding body
Yes Yes Yes Yes Yes Yes Yes Yes Yes
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Table 2. Methodology characteristics
ASCO ESMO NICE SIGN START NHMRC NCI NCCN CCO
GL development
group
MultidisciplinaryYes Occasionally Yes Yes Yes Yes Yes Yes Yes
Methodological
experts
Yes No Yes Yes Yes Yes No No Yes
Patient
advocate
Yes No Yes Yes No Yes No Occasionally Yes
Policy
makers
No No No No No No No No No
Industry No No No No No No No No No
Review of
the evidence
Systematic,
explicit search
strategy and
on-line databases
Narrative, literature
search not fulfilling
the definition of SR
Systematic, explicit
search strategy and
on-line databases
Systematic, explicit
search strategy and
on-line databases
Narrative, literature
search not fulfilling
the definition of SR
Systematic, explicit
search strategy
and on-line databases
Narrative, literature
search not fulfilling
the definition of SR
Narrative, literature
search not fulfilling
the definition of SR
Systematic, explicit se
arch strategy and
on-line databases
Process of GL
development
Drafting of GL by
the Expert Panel,
Review by external
reviewers, two HSC
reviewers and two
reviewers from ASCO
Board of Directors.
ASCO Board of
Directors decides on
GL and sends it to
Expert Panel for
final revision.
The Editorial Board
assigns GLs to
Subject Editors who
invite authors.
After author
submission of a
draft, it is reviewed
by 2-5 external
ESMO Faculty
members. SE and
Editorial Board
decide and
finalise GL.
The Secretary of
State for Health
commissions the
GL production to
NCC for Cancer
which designs a
Scope document
and appoints a
GDG. GDG
produces a draft
which is reviewed
from guideline
review panels
and stakeholders
and is validated
before finalisation.
The SIGN Council
appoints a GL GDG
which produces a
draft. The draft
is revised at the
National Open
Meeting, by expert
panels and
stakeholders. The
draft is finalised by
the SIGN
Editorial Group.
The authors
produce a draft,
which is further
processed by GL
Editors and
reviewed by one
external reviewer.
The GL is finalised
by the START
Steering
and Scientific
Committee and
undergoes ongoing
external review
online by cancer
societies.
An external body
applies to the Health
Advisory Committee
of the NHMRC and
submits periodic
progress reports of
the GL development.
The GL is reviewed
by stakeholders and
by an expert review
panel. HAC decides
for NHMRC
endorsement.
Each PDQ Editorial
Board meets
monthly to study
evidence and
produces a PDQ
draft for each
tumour type.
The draft is
reviewed by the
corresponding
Editorial Advisory
Board. The PDQ
EB finalises
the PDQ.
The Guideline
Steering Committee
appoints the GL
panels with member
from each institution.
The GL panel
produces the first
draft which
undergoes external
stakeholder and
institutional review
in each NCCN
centre. The GL
panel finalises
the GL.
The PEBC Disease
Site Group produces
a GL draft which is
reviewed by an
internal PEBC
Report Approval
Panel. The draft is
mailed to 80-120
practicing external
physicians for review.
The GL if finalised by
the Practice GL
Coordinating
Committee.
Consensus and
authorship
Informal consensus,
several authors
Informal consensus,
2–3 authors
Formal consensus,
committee
authorship
Formal consensus,
committee
authorship
Informal consensus,
committee
authorship
Informal consensus,
committee authorship
Informal consensus,
committee
authorship
Informal consensus,
committee authorship
Formal consensus,
committee authorship
Legal review Yes No Yes Yes No Yes No Yes Yes
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out by the guideline development group not according to the
strict definition of systematic review (usually without provision
of data on the selection and synthesis of evidence) in the case of
ESMO, START, NCI and NCCN. The process of guideline
drafting followed a standard core format in all cases: a task
force or single author, on the basis of existing relevant evidence,
produced a first draft which was shaped into the final guideline
through an interactive process of peer review and feedback-
based modifications. Committee authorship was the rule in
most guidelines with the exception of ASCO and ESMO in
which a number of scientists authored each GL (ranging from 2
to 10). The review process focused mainly on peer review by
independent experts in ASCO, ESMO, START, NCI and
NCCN guidelines, while it included a public consultation
process with feedback received from stakeholders (patients,
public, industry, professional organisations, community
health professionals and health providers) in NICE, SIGN,
NHMRC and CCO. Moreover, some organisations (NICE,
START, NHMRC) implemented a second ‘validation’ phase,
during which guidelines were available for scrutiny and
feedback from professionals and public before finalisation.
Decisions were reached by formal or informal consensus in
the development groups, with appropriate care taken to
provide information on divergent views or lack of evidence for
unanimous strong recommendations in all cases. Following
review, the revised guidelines were formatted and approved by
the CPG development groups and supervising editorial
boards.
guideline structure and content characteristics
Most organisations issued ‘comprehensive’ guidelines that
encompass all diagnosis, staging, risk assessment and
management recommendations for a specific tumour type
(Table 3). Notable exceptions were ASCO and CCO that
produced guidelines focused on ‘narrower’ topics or questions
set within a specific tumour type. The scope of the latter was to
study available evidence and provide recommendations for
specific clinical circumstances (i.e. adjuvant taxanes in early
breast cancer). NICE produced both comprehensive and more
focused guidelines, the latter being more numerous. The
number of active guidelines ranged from 12 to 108, the societies
covering all tumours with comprehensive guidelines being
ESMO, START, NCI and NCCN. The size of produced
guidelines exhibited significant variation, ranging from 2 to 368
pages and citing from 15 to 1000 references. Consequently,
some GLs were meant to be summary clinic guides while others
served as reference source documents. The structure of each
guideline in thematic sections was grossly standardised in all
cases. START and NCI had their guidelines formatted as
on-line hypertexts with convenient hyperlinks incorporated in
them. Most guidelines included synopses of recommendations
in the form of summaries or tables. A characteristic feature of
NCCN CPG was the presentation of recommendations in flow
diagrams or algorithms according to disease and patient
characteristics. Although in the majority of cases, a system for
grading the level of supporting evidence (LOE) and the strength
(grade) of recommendations (GOR) was used, it was not
standardised: the US Preventive Services Task Force, ASCO,
SIGN, START, NCI, NCCN and GRADE tools were applied.
Most used the study design and type as the main LOE criterion,
methodology rigour and consistent results as GOR criteria. Still
in some instances, strength of end points and consensus level
were considered too. In view of the absence of unanimous
agreement on an ideal, common LOE-rating scheme, ASCO
and CCO adopted a narrative description of the type and
quality of evidence. Cost data for implementation of
recommendations were furnished in practice only by NICE,
SIGN and NHMRC. Quantitative cost reports were given in all
cases by NICE and occasionally by NHMRC, while SIGN only
provided verbal, qualitative estimates of resource implications.
Of note, CPG of importance for the definition of
reimbursement policies were commonly the ones produced by
governmental agencies and containing more detailed health
economic data (NICE, SIGN and NHMRC). Periodic screens
for emerging, relevant medical literature were carried out by the
editors or the CPG development groups either with reiteration
of the review/validation cycle (ASCO, ESMO, NHMRC, NICE,
SIGN, NCCN and CCO) or without it (NCI and START). In
practice, some guidelines took 2–3 years to develop and updates
were issued at more sparse (3- to 5-year) intervals (NICE,
SIGN, NHMRC and CCO). The net effect, updated guidelines,
occurred at yearly intervals only for ESMO, NCI and NCCN.
Finally, conflict of interest statements of guideline developers
could be retrieved in all guidelines except for START, NCI and
NHMRC before 2004 and ESMO before 2007.
implementation and evaluation characteristics
The composition of the development group, methodology
followed, size, structure and target users of each guideline
ultimately defined its orientation for use and context (Table 4).
CPG issued by ESMO and the summary Quick Reference
Guides issued by NICE, SIGN and CCO as well as the Flow
Chart features of NCCN were intended for quick consultation
by the physician in the office or clinic. The full guideline
versions of NICE, SIGN, NCCN and CCO and the CPG of
ASCO, START, NHMRC and NCI had the hallmark features of
reference documents: considerable size, detailed data and
numerous references. Most organisations seemed to promote
dissemination of issued CPG via standard strategies, such as
medical journals, publications, seminars or workshops, sessions
in professional organisation meetings, patient materials and
Web site availability of downloadable CPG. Flow sheets for
hospital practices, implementation plans for regional practices
and other forms of electronic material were used as well.
Adherence to the guidelines was not legally binding for the
practicing physician. However, though acknowledging that the
CPG does not override the responsibility of health care
professionals to make individualised decisions appropriate to
the circumstances of each patient, NICE and SIGN stated that
institutions providing NHS-funded care would be expected to
adhere to the guidelines. Moreover, health care professionals
were requested to document the reasons for not following
a guideline. These facts, along with the importance of the NICE
and SIGN guidelines in the definition of reimbursement health
care policies, were likely to constitute them more binding for
the physician. Targeted health professionals encompassed
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Table 3. Guideline structure and content characteristics
ASCO ESMO NICE SIGN START NHMRC NCI NCCN CCO
Comprehensive
for tumour
type and site
No. GL with
specific focused
topics.
Yes Some. Several GL
with specific
focused topics.
Yes Yes Yes Yes Yes. Some
GL are
structured by
organ site.
No. GL with
specific focused
topics.
Number of
existing
guidelines
21 39 13 12 67 12 80 34 108
Advanced
breast cancer
No (7) Yes, 2007 No (11) Yes, 2005 No Yes, 2001 Yes, 2007 Yes, 2007 No (9)
Advanced
colon cancer
No (3) Yes, 2007 No (6) Yes, 2003 Yes, 2007 Yes, 2005 Yes, 2007 Yes, 2008 No (6)
Advanced
lung cancer
Yes, 2003 Yes, 2007 Yes, 2005 Yes, 2005 No Yes, 2004 Yes, 2007 Yes, 2008 No (9)
Pages 24 2–3 114–136 51–66 15–25 215–368 40 60–100 35–40
References 293 15–20 450–600 214–345 200–300 407–1000 350 169–247 116–124
Structure Diagnosis,
Staging, Treatment,
FU, Lifestyle
changes
Incidence,
Diagnosis,
Staging, Risk,
Management,
FU
Access to
services,
Diagnosis,
Staging,
Treatment,
Palliative–
supportive care,
Organisation of
services, Cost-
effectiveness,
FU,
Implementation,
Research
Diagnosis,
Investigations,
Management,
Palliative–
psychological
care, FU,
Informations
for patients,
GL Development,
Implementation
and Research
On-line
hypertext with
hyperlinks:
General,
Pathology–
biology,
Diagnosis,
Staging,
Prognosis,
Treatment,
Late sequelae,
FU
Epidemiology,
Impact,
Prevention
screening,
Patient
communication,
Diagnosis
staging,
management,
Supportive care,
Quality of life,
FU
On-line
hypertext with
hyperlinks:
Epidemiology,
Genetics,
Diagnosis,
FU, Staging,
Management
Algorithm flow
charts followed
by manuscript
text: Diagnosis
and investigations,
Staging, Risk,
Primary
treatment and
adjuvant therapy,
Surveillance,
Salvage therapy
Summary of
recommendations
followed by
full report:
Question, Methods,
Evidence,
Interpretation
discussion,
Recommendations,
Ongoing Trials,
External review
Grading of
evidence
Narrative
description
ASCO LOE
(I–V) and
GOR (A–D)
SIGN LOE
(1–4) and
GOR (A–D)
SIGN LOE
(1–4) and
GOR (A–D)
START LOE
(1–3, C, R)
US Preventive
Services Task
Force LOE
I–IV
NCI LOE
according to
study design
(1–3) and
strength of
end points
(A–D)
NCCN LOE
and consensus
level make up
the NCCN
Category of
Evidence (1–3)
Narrative
description
Cost data Desirable, but
optional
No Health economic
analyses and
Cost Impact
Reports
Qualitative
resource
implications
No Yes No No No
Literature
search
2 years Yearly 2 years 2 years Yearly Unknown 8 times a year Yearly Unknown
Update 2–3 years Yearly 3–5 years 3–5 years 2–3 years 5 years Yearly Yearly 3 years
Conflicts
of interest
stated
Yes Yes, since
2007
Yes Yes No Yes, since 2004 No Yes Yes
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Table 4. Implementation and evaluation characteristics
ASCO ESMO NICE SIGN START NHMRC NCI NCCN CCO
Use Reference
document
Quick office
application
Reference
document.
Quick Reference
Guides exist
Reference
document.
Quick Reference
Guides exist
Reference
document
Reference
document.
Summary
Recommendation
Tables exist
Reference
document
Both reference
document
(manuscript text)
and Quick office
application
(algorithms)
Reference
document.
Summary Guideline
versions exist
Dissemination
and implementation
tools
Journal of
Clinical Oncology,
Journal of Oncology
Practice, ASCO
meeting sessions.
Summaries for health
professionals and
patients, Flow sheets
for patient care in
hospitals, PDA software,
ASCO and PLWC
Web site.
Annals of
Oncology,
ESMO and
ESMO-labelled
meetings, ESMO
newsletter, booklets,
PDA software,
ESMO Web site.
NICE
publications,
Quick Reference
Guides,
Information
for patients,
Implementation
plans for regional
practices, Cost
Reports, NICE
Web site.
SIGN publications,
Quick Reference
Guides,
Information for
patient sections,
NHS Trust
workshops,
SIGN Web site.
ESO, EONS,
ESTRO,
ESSO meetings,
START
Web site.
NHMRC publications,
Patient Guideline
booklets, National
seminars, NHMRC
and external body
Web sites.
NCI hypertexts,
NCI Web site,
PDA software,
NCI meetings,
NCI seminars,
PDQ for patients.
NCCN
publications,
Patient information
guideline versions,
Guideline symposia,
NCCN Annual
meeting, Journal
of NCCN, NCCN
Web site.
Canadian Medical
Association Clinical
Practice Infobase
and CCO Web site,
Journal of CMA,
Journal of Clinical
Oncology,
newsletters, patient
publications,
CCO workshops.
Binding for
physicians
No No Adherence is
expected
Adherence is
expected
No No No No No
Targeted health
professionals
Multidisciplinary
Oncology
Medical
Oncology
Multidisciplinary
Oncology and
other health
specialities
Multidisciplinary
oncology and
other health
specialities
Multidisciplinary
Oncology
Multidisciplinary
Oncology and
other health
specialities
Multidisciplinary
Oncology and
other health
specialities
Multidisciplinary
Oncology
Multidisciplinary
Oncology and
other health
specialities
Range United States Europe England and
Wales NHS
Scotland NHS Europe Australia United States United States Ontario, Canada
Evaluation of GL
implementation
Membership surveys,
web downloads
ESMO meeting
questionnaires,
web downloads
NHS audit,
NICE
publications,
web downloads
NHS audit,
SIGN
publications,
web downloads
Delphi processus
questionnaires,
web downloads
NHMRC audit Web
downloads
Web downloads,
publications
Web downloads
Evaluation
of patient/health
system outcomes
Occasional reports
from Quality
Oncology Practice
Initiative
Occasional
surveys
Yearly reports
from the
ERNIE
database
Periodic reports
from NHS
audit projects
No Occasional reports
from surveys and
registry data
Cancer Trends
Progress Reports
every other year
No Yearly reports
from the Cancer
System Quality
Index
Metrics on web No No No No No No Yes No Yes
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a broad group of physicians, nurses and other health care
workers in NICE, SIGN, NHMRC, NCI and CCO. In contrast,
it was more restricted to physicians caring for cancer patients in
ASCO, ESMO, START and NCCN guidelines. The region for
guideline implementation was defined by the developing body
and ranged from regions (Ontario and Canada) to countries
(Australia, United States and UK) and continents (Europe).
The extent of the ‘catchment area’ was inversely related to the
binding nature, regulatory aspect, health economic analysis and
reimbursement impact of guidelines.
The evaluation of the implementation of guidelines and their
impact on patient and health system outcomes (survival,
quality of life, cost-effectiveness, resource utilisation) presented
considerable heterogeneity among issuing organisations. Audits
on the basis of electronic databases, health system registries,
physician/patient surveys, opinion meetings or mailed
questionnaires, publication titrage and number of Web site
downloads were most commonly used in various settings.
However, the extent, systematic nature and data capture of
these audits varied significantly. Some organisations (CCO,
NICE, SIGN, NCI, ASCO) regularly issued evaluation reports
based mainly on electronic/registry data capture while others
(NHMRC, ESMO, NCCN, START) carried out periodic
assessment of GL impact by means of surveys at irregular time
intervals. It should be stressed that only CCO and NCI had
evaluation data indicative of their implementation/impact on
health care freely available on their Web sites.
scientific agreement of formulated
recommendations
All screened organisations showed significant agreement in the
scientific content of formulated recommendations for the
management of patients with NSCLC, the leading cause of
cancer mortality in developed societies. Using the SIGN
guidelines, issued in 2005, as a common comparator, we
observed only minor and few, if any, major disagreements in
the other CPG (Table 5). They were observed in areas such as
the application of low-dose spiral CT for NSCLC screening, the
role of positron emission tomography and routine brain
imaging in staging, the recommendation for adjuvant
chemotherapy, the role of continuous hyperfractionated
accelerated radiotherapy (CHART) as definite radiotherapy for
medically inoperable cases or locally advanced disease.
Differences were also seen in the number of palliative
chemotherapy cycles to be administered, active second-line
chemotherapy drugs, recommendation of anti-EGFR-targeted
agents and on the intensiveness, timing, modalities of follow-
up. Most minor differences were attributable to different
philosophies on resource availability and utilisation, rapidity of
adoption of emerging medical breakthroughs and role of the
patient in clinical decision making. Differing views on matters
such as persistence to active treatment with antineoplastic
therapies, evaluation of quality-of-life values, cost-effectiveness
and quality-adjusted life year thresholds may also have played
a role. Moreover, the fear of litigation, the source of health care
funds and the psychological/social contexts probably differed
between geographical areas, contributing to some minor
disagreements. Most importantly, the rare major scientific
disagreements were due to different rate of update of guidelines
and are quite likely to disappear when the chronologically older
versions of some CPG are replaced by updated ones. For
example, guidelines issued before 2006 did not contain
recommendations on some second- to third-line chemotherapy
or anti-EGFR regimens for patients with advanced NSCLC.
This highlights the importance of timely updates of cancer
guidelines.
discussion
The rapid progress in the fields of molecular biology, oncology
and supportive care faced oncologists with an agreeable
challenge: to make individualised judgements on the best
available treatment of the most relevant health outcome, while
respecting patient preferences. CPG are recommendations
systematically developed by experts with access to available
evidence in order to help doctors and patients identify
appropriate health care for each setting. Soon after embarking
on guideline development projects, the scientific community
became aware that standardisation was the key to success: the
processes of laying down the clinical question to be answered
by the guideline, the development of the guideline, the
collection and synthesis of the evidence, the formulation of
recommendations, the report, evaluation and adaptation of
guidelines needed to become standardised in order to guarantee
high methodological quality and dissemination [3, 6, 7, 13, 14].
Several tools and instruments were developed for this goal and
were met with satisfactory acceptance. PICO, an acronym for
Population, Intervention, Comparison, Outcome, is
a structured approach to formatting questions that a guideline
should address [11]. Formal consensus techniques have been
developed to facilitate merging and synthesis of different
opinions among working group members [17]. Investigators
proposed several algorithms for development of guidelines, like
the Practice Guidelines Development Cycle devised by the
Cancer Care Ontario group [18]. Several quality-rating scales
have been published so as to evaluate the quality, quantity,
rigour and consistency of the evidence base (GRADE, SIGN, US
Preventive Services Task Force, SORT), thus assessing the level
of evidence and strength of recommendations [9, 10, 19, 20].
The AGREE instrument is a validated systematic framework for
assessing key components of guideline quality, including scope/
purpose, stakeholder involvement, rigour of development,
clarity, applicability and editorial independence [7]. Adaptation
tools, like ADAPTE, represent validated processes for adapting
existing guidelines to different economic, cultural or
geographical contexts [8].
In our examination of nine popular Anglophone CPG, we
observed that the realisation of the need for adherence to
methodological standards resulted in relative homogeneity in
several key components of guidelines. They were developed by
working groups of 10–30 members, a number allowing for both
global representation of stakeholders and flexibility, composed
of multidisciplinary oncology-oriented health professionals in
the absence of industry or government [11, 21]. Editorial
independence from the funding body was guaranteed and
recommendations were on the basis of available evidence,
searched in on-line databases. The final product was shaped
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through an interactive process of opinion synthesis taking place
between authors, reviewers, supervising bodies and involved
stakeholders. Most CPG-provided comprehensive
recommendations for diagnosis, staging, management and
follow-up of patients with specific malignancies, were updated
periodically and disseminated via printed and electronic
material in target users. Finally, the scientific content of
formulated recommendations showed high rates of agreement
between guidelines issued.
However, a deeper examination of data reveals divergence
within similarity. CPG examined were produced by both
professional organisations and ones funded by or affiliated to
the government. This might bear on the end-product, the
parameters to consider, the priorities for intended outcomes
and the targeted users. We believe that CPG issued by
professional organisations may rank patient benefit as the
absolute priority, while governmental CPG be obliged to
consider cost-effectiveness data and optimal allocation of finite
health resources. Proposals for guideline development could
stem from any interested person versus members of the
organisation or expert committees only. The composition of
guideline development groups varied considerably: the
definition of multidisciplinarity ranged from involvement of
surgical, medical and radiation oncologists to that of physicians
of different specialities or involvement of physicians, nurses,
pharmacists, physical therapists, social workers,
epidemiologists, statisticians, health care managers, economists
and patient representatives. Recommendations were on the
basis of evidence. Still, on several occasions that were distilled
via on-line database searches with no methodology data
provided, a strategy with implicit faith on expert opinion and
‘illuminated’ bias of the developer. The latter factor is, in our
opinion, often a strong point but may well become a major
source of inappropriate bias. In other cases, exhaustive search
strategies with strictly defined criteria were implemented. This
approach emphasises systematician belief in the value of data
mining, though at risk of drawbacks such as the burden of
effort, the risk of mining outdated, irrelevant or redundant data
and of producing extensive guideline statements. Moreover, the
review process varied from peer review by experts to extensive
public consultation with patients, public, industry and
organisations involved. Even the structure, focus and size of
guidelines showed considerable variability, a comprehensive
approach encompassing all aspects of management of a specific
tumour was observed in parallel to more focused guidelines
providing recommendations for specific clinical situations,
therapeutic interventions or risk groups. Guidelines appeared
as a basic set of recommendations, as web-based hypertexts or
as voluminous textbooks up to 1000 pages long, implying
different philosophies of use as either clinic guides or reference
manuscripts. Levels of evidence and strength of
recommendations were classified by means of several different
schemes or simply narratively described [9, 10, 19, 20, 22]. Cost
data were considered crucial, optional or irrelevant and
guidelines were regarded as supportive or at times restrictive for
treating physicians [23]. Updates were produced whenever
Table 5. Scientific agreement of formulated recommendations for non-small-cell lung cancer (NSCLC)
ASCO 2003 ESMO 2008 NICE 2005 SIGN 2005
(comparison standard)
START NHMRC 2004 NCI 2007 NCCN 2008 CCO 2006–2007
Epidemiology,
screening and
presentation
80–100 80–100 80–100 80–100 60–80 60–80 –
Diagnosis 80–100 80–100 80–100 – 80–100 60–80 60–80 80–100
Staging 80–100 80–100 80–100 – 80–100 80–100 60–80 80–100
Surgery 80–100 80–100 80–100 – 80–100 80–100 80–100 80–100
Radiotherapy 60–80 60–80 60–80 – 80–100 40–60 60–80 80–100
Chemotherapy 60–80 60–80 80–100 – 40–60 60–80 60–80 60–80
Other therapies
(biologics)
40–60 40–60 80–100 – 40–60 40–60 40–60 40–60
Palliative and
supportive
care
80–100 80–100 80–100 – 80–100 60–80 80–100 –
Follow-up 60–80 60–80 80–100 – 80–100 – 40–60 80–100
Implementation
and Research
– – 80–100 – – – – –
Mean agreement
score (%)
89 89 98 – 91 80 80 91
Measurement Scale of Rate of Agreement (SIGN NSCLC guidelines as a common comparator)
0%–20%: Radically different
20%–40%: Numerous major scientific disagreements present
40%–60%: Few major scientific disagreements present
60%–80%: Only minor scientific disagreements present
80%–100%: Absolute scientific agreement
In blank fields, no information is available. START has not a comprehensive NSCLC guideline for comparison.
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relevant data appeared or periodically every 1 year or up to 5
years. Various CPG were applicable in regions, countries or
continents and targeted as users oncologists only, physicians of
different specialities or globally health professionals, health
managers and patients.
The observed heterogeneity could be interpreted by two
distinct phenomena: lack of standardisation and lack of
unanimous acceptance of developing tools or unavoidable
emergence of flexible divergence in order to accommodate
different socioeconomic contexts. We believe that both
mechanisms are at play. No standard algorithm for producing
CPG is of proven superiority, the parameters to consider and
methods to measure such superiority being poorly defined. No
unique rating scale for evaluating level of evidence/strength of
recommendation has been widely adopted so far. We believe
that the GRADE scheme is the most likely candidate to gain
broad acceptance in health care disciplines, as it quantifies the
strength of recommendations taking into account the estimate
of effect of an intervention, the design, execution, consistency,
precision, reporting bias of studies, the patient health benefits
versus harms and the health system costs. Still, drawbacks are
present: it does not completely eliminate subjectivity, it loses
information through categorisation, there is no guarantee
about its generalisability. Finally, its application will require
significant additional resources. Adaptation policies for CPG
are only recently beginning to be developed. The varying
guideline update intervals reflect both lack of standardised,
electronic update tools as well as differential health system
flexibility. There are varying amount of efforts invested in
guidelines with extensive data mining and consultation
processes versus more flexible datasets. They also mirror
different perception of the rapidity and clinical applicability of
research breakthroughs [24].
We found guideline evaluation to be one of the most poorly
implemented and among the most diverse aspects of the
organisations that we screened. Any evaluation strategy may
study the implementation/adoption of the guideline by the
target user and most importantly, its impact on patient,
physician and health system outcomes. We encountered a range
of evaluation philosophies ranging from periodic, ‘loose’
evaluations on the basis of surveys at irregular intervals to
regular ones with well-organised data capture. Even among the
latter, in only two instances were evaluation data freely
available online. Inherent problems with evaluation approaches
are the definition of parameters (end points) to be studied, the
resources and infrastructure required for reliable data collection
and the techniques used to analyse the data. In oncology, most
evaluation analyses study survival or quality of life as relevant
patient outcome indices, GL adoption as physician outcomes
and optimal resource allocation, cost-effectiveness, timely and
quality care as health system outcome measures. We strongly
believe that further validation and improvement of issued
guidelines can only be sought after systematic, reliable
evaluation of their impact on health outcomes. Such evaluation
could generate invaluable information on benefits, deficits and
areas for change of aspects of guideline development, reporting
and end-products.
Heterogeneity stemming from flexibility in order to
accommodate different socioeconomic and cultural
backgrounds is more controversial. Such heterogeneity of CPG
was often seen as a negative phenomenon, interfering with their
quality, dissemination and adoption, thus worth eliminating.
International collaboration has been deemed necessary to deal
with it, avoid duplication of efforts, minimise costs and
guarantee high quality [3, 14, 25]. However, a prerequisite
for such cooperative efforts is consensus on the end-product to
be had. Such consensus is not always established, as may be
seen by examining the definition of guidelines cited in the
introduction. CPG are ‘systematically developed statements’,
but how do we define ‘systematic’? Should one use the strict
definition of the term, which is evaluated by 21 parameters in
the QUOROM instrument and by 29 in the one suggested by
Vigna-Taglianti, or stick to the more liberal definition of
literature search in on-line databases [26, 27]? The goal is to
identify the most relevant evidence which is still evaluated and
synthesised by the expert opinions of developers and reviewers.
Accordingly, evidence-based recommendations should perhaps
more realistically be termed bias-minimised recommendations.
CPG aim to ‘assist practitioner and patient decisions’. It is
crucial to define which practitioner would that be. The medical
oncologist only? The medical, radiation or surgical oncologists,
based on tertiary reference centres? The community physicians,
other health specialists or health professionals? It is also pivotal
to consider whether health provider input is expected to
influence decisions reached. Moreover, patient involvement in
decision making may vary according to social, financial and
cultural contexts, therefore making this parameter less concrete
[15, 28]. Finally, decisions are expected ‘about appropriate
health care for specific clinical circumstances’, the latter
definition being as heterogeneous at it gets in real life.
Appropriate health care could be any relatively safe treatment
providing some survival or quality-of-life benefit or only a cost-
effective therapy that provides substantial clinical benefit with
reasonable and affordable resource allocation. Is it feasible to
homogeneously rank benefits and costs of interventions in
different societies, such as poor or rich countries, privately
funded or nationally funded health systems where resources
and criteria for their allocation differ? Specific clinical
circumstances also vary by culture, health system, country,
medical technology and resources available [29–31]. Moreover,
there is disagreement on how quickly appropriate health care
changes and specific clinical circumstances evolve, hence
a different opinion on the optimal frequency of guideline
updates [24].
We argue that such CPG heterogeneity is not detrimental for
guideline quality, dissemination and adoption. A key point is to
define clearly what the guideline intends to do, for whom and
in which circumstances. There are different needs to be met by
CPG in various health systems, societies, among health
professionals, patients and organisational structures. Provided
methodological standards are adhered to so as to guarantee
high-quality, heterogeneity in aspects of development,
structure, context, target user and end point definitions may be
needed in order to better meet divergent patient and physician
demands in a caleidoscopic world. Evaluation of guideline
impact on health outcomes in each societal background should
help further refine the end-product. International collaboration
is certainly the one to build on, though with room for variance.
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